Even though I like Orion as a company, the price climbed recently too high to make sense to me.
There are other companies in Finland of same quality, with higher dividend yield, better future prospects and more reasonable valuation.
It seems that many companies in pharmaceutical sector are valued high (P/E > 25) - just like Orion was when I sold it. It seems bit challenging given the headwinds most companies need to face with blockbuster drugs going out of patent protection.
No comments:
Post a Comment